CX1763
CX1763 is an AMPAR allosteric modulator. CX1763 allosterically potentiates glutamate-evoked currents, accelerates channel opening, and increases the surface levels of AMPAR containing Glur2 (R). CX1763 enhances synaptic transmission in the rat hippocampus. CX1763 improves attention in rats and attenuates amphetamine-induced hyperactivity in mice. CX1763 can be used in studies related to attention deficit hyperactivity disorder and opioid-induced respiratory depression.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1086378-73-5
- 分子式: C14H17N3O3
- 分子量:275.30
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
iGluR アイソフォーム固有の製品をすべて表示
More
生物活性
|
AMPA Receptor |
CX1763 (100 μM) acts as a low-impact AMPA receptor positive allosteric modulator in rat brain membranes and neurons, increasing [3H]AMPA binding and peak glutamate-induced currents without intrinsic agonism up to 100 μM, and upregulating calcium-impermeable GluR2(R)-containing receptors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
CX1763 (1-5 mg/kg; i.p.; single administration) improves specific attention parameters (shortens response latency, reduces premature responses) in the 5CSRTT ADHD rat model at the 5 mg/kg i.p. dose, while increasing omission errors without altering the correct response rate[1].
CX1763 (1-18 mg/kg; i.p.; single administration) dose-dependently reduces amphetamine-induced hyperactivity in mice, with an AD50 of 2 mg/kg, and completely reverses this symptom at 18 mg/kg via intraperitoneal injection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Long-Evans (male, 250-350 g)[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; single dose
-
Result:Significantly potentiated hippocampal fEPSP amplitude by ~20% at 15 minutes post-dose.
Peaked at ~15 minutes post-dose.
Declined to baseline by 100-120 minutes post-dose.
-
Animal Model:hooded Wistar (male, 250-310 g, 5-Choice Serial Reaction Time Task trained)[1]
-
Dosage:1 mg/kg; 5 mg/kg
-
Administration:i.p.; single dose
-
Result:Did not significantly alter 5CSRTT parameters at 1 mg/kg.
Significantly decreased correct response latency at 5 mg/kg.
Significantly decreased the percentage of premature responses at 5 mg/kg.
Significantly increased omission errors at 5 mg/kg.
Did not significantly improve the percentage of correct responses at 5 mg/kg.
-
Animal Model:CD1[1]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg; 18 mg/kg
-
Administration:i.p.; single dose
-
Result:Dose-dependently reduced amphetamine-induced hyperactivity, with an AD50 of 2 mg/kg.
Significantly reduced hyperactivity at doses of 3-18 mg/kg.
Completely reversed amphetamine-induced hyperactivity to baseline levels at 18 mg/kg.
化学情報
-
CAS 番号 1086378-73-5
-
分子量 275.30
-
分子式 C14H17N3O3
-
SMILES
CN([C@H]1CC[C@@H](CC1)O)C(C2=CC3=NON=C3C=C2)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
CX1763 関連分類
HY-182631 関連分類
Powered by Bioz